Patrick J. Flynn

18.9k total citations · 3 hit papers
145 papers, 11.1k citations indexed

About

Patrick J. Flynn is a scholar working on Oncology, Pulmonary and Respiratory Medicine and Genetics. According to data from OpenAlex, Patrick J. Flynn has authored 145 papers receiving a total of 11.1k indexed citations (citations by other indexed papers that have themselves been cited), including 92 papers in Oncology, 50 papers in Pulmonary and Respiratory Medicine and 26 papers in Genetics. Recurrent topics in Patrick J. Flynn's work include Colorectal Cancer Treatments and Studies (31 papers), Cancer Treatment and Pharmacology (28 papers) and Glioma Diagnosis and Treatment (17 papers). Patrick J. Flynn is often cited by papers focused on Colorectal Cancer Treatments and Studies (31 papers), Cancer Treatment and Pharmacology (28 papers) and Glioma Diagnosis and Treatment (17 papers). Patrick J. Flynn collaborates with scholars based in United States, Canada and China. Patrick J. Flynn's co-authors include Al B. Benson, Mark R. Somerfield, Gary R. Morrow, Charles L. Loprinzi, Kendrith M. Rowland, Kurt A. Jaeckle, Jeffrey J. Kirshner, Shaker R. Dakhil, Joseph A. Roscoe and Jan C. Buckner and has published in prestigious journals such as The Lancet, Journal of Clinical Oncology and SHILAP Revista de lepidopterología.

In The Last Decade

Patrick J. Flynn

145 papers receiving 10.8k citations

Hit Papers

align trajectories sort by overperformance

What are hit papers?

Hit papers significantly outperform the citation benchmark for their cohort. A paper qualifies if it has ≥500 total citations, achieves ≥1.5× the top-1% citation threshold for papers in the same subfield and year (this is the minimum needed to enter the top 1%, not the average within it), or reaches the top citation threshold in at least one of its specific research topics.

American Society of Clinical Oncology Recommendations on Adjuvant Chemotherapy for Stage II Colon Cancer

2004 1.1k citations Al B. Benson, Patrick J. Flynn et al. Journal of Clinical Oncology profile →
Gemcitabine Alone Versus Gemcitabine Plus Radiotherapy in Patients With Locally Advanced Pancreatic Cancer: An Eastern Cooperative Oncology Group Trial

2011 604 citations Patrick J. Loehrer, Yang Feng et al. Journal of Clinical Oncology profile →
Phase III Study Comparing Gemcitabine Plus Cetuximab Versus Gemcitabine in Patients With Advanced Pancreatic Adenocarcinoma: Southwest Oncology Group–Directed Intergroup Trial S0205

2010 500 citations Patrick J. Flynn, Kendrith M. Rowland et al. Journal of Clinical Oncology profile →

Author Peers

Peers are selected by citation overlap in the author's most active subfields. citations · hero ref

Author						Papers	Cites
Patrick J. Flynn	6.9k	2.6k	2.2k	2.2k	1.6k	145	11.1k
Shaker R. Dakhil	9.2k 1.3×	5.1k 1.9×	3.3k 1.5×	3.0k 1.4×	3.1k 2.0×	313	16.4k
Aung Naing	5.8k 0.8×	3.0k 1.1×	4.4k 2.0×	1.4k 0.6×	3.0k 2.0×	483	12.5k
Javid J. Moslehi	6.6k 1.0×	2.2k 0.8×	3.7k 1.7×	794 0.4×	1.3k 0.8×	211	16.0k
Vera J. Suman	7.0k 1.0×	2.3k 0.9×	3.0k 1.4×	1.7k 0.8×	3.6k 2.3×	273	14.8k
Sandro Barni	7.7k 1.1×	4.3k 1.7×	1.9k 0.9×	1.5k 0.7×	2.0k 1.3×	479	14.5k
Siqing Fu	4.1k 0.6×	2.4k 0.9×	3.8k 1.7×	1.2k 0.6×	2.4k 1.6×	412	9.6k
Nicholas Pavlidis	8.7k 1.3×	2.4k 0.9×	2.3k 1.0×	3.0k 1.3×	1.7k 1.1×	324	13.2k
Hans Wildiers	7.5k 1.1×	3.3k 1.3×	2.7k 1.2×	1000 0.5×	3.4k 2.2×	390	14.6k
Wolff Schmiegel	6.2k 0.9×	2.3k 0.9×	4.1k 1.9×	2.2k 1.0×	2.2k 1.4×	267	13.1k
G. Milano	7.8k 1.1×	3.1k 1.2×	4.1k 1.8×	1.4k 0.6×	1.5k 1.0×	392	12.3k

Countries citing papers authored by Patrick J. Flynn

Since Specialization

Citations

This map shows the geographic impact of Patrick J. Flynn's research. It shows the number of citations coming from papers published by authors working in each country. You can also color the map by specialization and compare the number of citations received by Patrick J. Flynn with the expected number of citations based on a country's size and research output (numbers larger than one mean the country cites Patrick J. Flynn more than expected).

Fields of papers citing papers by Patrick J. Flynn

Since Specialization

Physical SciencesHealth SciencesLife SciencesSocial Sciences

This network shows the impact of papers produced by Patrick J. Flynn. Nodes represent research fields, and links connect fields that are likely to share authors. Colored nodes show fields that tend to cite the papers produced by Patrick J. Flynn. The network helps show where Patrick J. Flynn may publish in the future.

Co-authorship network of co-authors of Patrick J. Flynn

This figure shows the co-authorship network connecting the top 25 collaborators of Patrick J. Flynn. A scholar is included among the top collaborators of Patrick J. Flynn based on the total number of citations received by their joint publications. Widths of edges represent the number of papers authors have co-authored together. Node borders signify the number of papers an author published with Patrick J. Flynn. Patrick J. Flynn is excluded from the visualization to improve readability, since they are connected to all nodes in the network.

All Works

Sort: Min cites: Since: Top N: Style:

20 of 20 papers shown

Stearns, Vered, Opeyemi A. Jegede, Victor T. Chang, et al.. (2024). A Cohort Study to Evaluate Genetic Predictors of Aromatase Inhibitor Musculoskeletal Symptoms: Results from ECOG-ACRIN E1Z11. Clinical Cancer Research. 30(13). 2709–2718. 4 indexed citations

Muscarella, Peter, Tanios Bekaii‐Saab, Kristi McIntyre, et al.. (2021). A Phase 2 Randomized Placebo-Controlled Adjuvant Trial of GI-4000, a Recombinant Yeast Expressing Mutated RAS Proteins in Patients with Resected Pancreas Cancer. SHILAP Revista de lepidopterología. 7(1). 8–19. 17 indexed citations

Jaeckle, Kurt A., Erin Twohy, Jesse G. Dixon, et al.. (2019). Phase I-II trial of imatinib mesylate (Gleevec; STI571) in treatment of recurrent oligodendroglioma and mixed oligoastrocytoma. North central cancer treatment group study N0272 (ALLIANCE/NCCTG). Journal of Neuro-Oncology. 143(3). 573–581. 8 indexed citations

Fehrenbacher, Louis, Reena S. Cecchini, Charles E. Geyer, et al.. (2019). NSABP B-47/NRG Oncology Phase III Randomized Trial Comparing Adjuvant Chemotherapy With or Without Trastuzumab in High-Risk Invasive Breast Cancer Negative for HER2 by FISH and With IHC 1+ or 2+. Journal of Clinical Oncology. 38(5). 444–453. 279 indexed citations

Yasenchak, Christopher A., Andres Forero‐Torres, Rodolfo Bordoni, et al.. (2015). Brentuximab Vedotin in Combination with Dacarbazine or Bendamustine for Frontline Treatment of Hodgkin Lymphoma in Patients Aged 60 Years and Above: Interim Results of a Multi-Cohort Phase 2 Study. Blood. 126(23). 587–587. 12 indexed citations

Deplanque, G., Martin Demarchi, Mohamed Hebbar, et al.. (2015). A randomized, placebo-controlled phase III trial of masitinib plus gemcitabine in the treatment of advanced pancreatic cancer. Annals of Oncology. 26(6). 1194–1200. 78 indexed citations

Merchan, Jaime R., Rui Qin, Henry C. Pitot, et al.. (2015). Safety and activity of temsirolimus and bevacizumab in patients with advanced renal cell carcinoma previously treated with tyrosine kinase inhibitors: a phase 2 consortium study. Cancer Chemotherapy and Pharmacology. 75(3). 485–493. 14 indexed citations

Galanis, Evanthia, S. Keith Anderson, Joon H. Uhm, et al.. (2013). Phase II Study of Bevacizumab in Combination with Sorafenib in Recurrent Glioblastoma (N0776): A North Central Cancer Treatment Group Trial. Clinical Cancer Research. 19(17). 4816–4823. 127 indexed citations

Tan, Winston, Amylou C. Dueck, Patrick J. Flynn, et al.. (2013). N0539 phase II trial of fulvestrant and bevacizumab in patients with metastatic breast cancer previously treated with an aromatase inhibitor: a North Central Cancer Treatment Group (now Alliance) trial. Annals of Oncology. 24(10). 2548–2554. 6 indexed citations

10.

Tan, Winston, Jacob B. Allred, Muhammad Salim, et al.. (2012). Phase II Interventional Study (N0337) of Capecitabine in Combination With Vinorelbine and Trastuzumab for First- or Second-Line Treatment of HER2-Positive Metastatic Breast Cancer: A North Central Cancer Treatment Group Trial. Clinical Breast Cancer. 12(2). 81–86. 6 indexed citations

11.

Loehrer, Patrick J., Yang Feng, Higinia R. Cárdenes, et al.. (2011). Gemcitabine Alone Versus Gemcitabine Plus Radiotherapy in Patients With Locally Advanced Pancreatic Cancer: An Eastern Cooperative Oncology Group Trial. Journal of Clinical Oncology. 29(31). 4105–4112. 604 indexed citations breakdown →

12.

Herbst, Roy S., Rafat Ansari, F. Bustin, et al.. (2011). Efficacy of bevacizumab plus erlotinib versus erlotinib alone in advanced non-small-cell lung cancer after failure of standard first-line chemotherapy (BeTa): a double-blind, placebo-controlled, phase 3 trial. The Lancet. 377(9780). 1846–1854. 316 indexed citations

13.

Jatoi, Aminah, Steven E. Schild, Nathan R. Foster, et al.. (2010). A phase II study of cetuximab and radiation in elderly and/or poor performance status patients with locally advanced non-small-cell lung cancer (N0422). Annals of Oncology. 21(10). 2040–2044. 40 indexed citations

14.

Galanis, Evanthia, Kurt A. Jaeckle, Matthew J. Maurer, et al.. (2009). Phase II Trial of Vorinostat in Recurrent Glioblastoma Multiforme: A North Central Cancer Treatment Group Study. Journal of Clinical Oncology. 27(12). 2052–2058. 283 indexed citations

15.

Jatoi, Aminah, Shaker R. Dakhil, Nathan R. Foster, et al.. (2008). Bortezomib, Paclitaxel, and Carboplatin as a First-Line Regimen for Patients with Metastatic Esophageal, Gastric, and Gastroesophageal Cancer: Phase II Results from the North Central Cancer Treatment Group (N044B). Journal of Thoracic Oncology. 3(5). 516–520. 26 indexed citations

16.

Ansell, Stephen M., David J. Inwards, Kendrith M. Rowland, et al.. (2008). Low‐dose, single‐agent temsirolimus for relapsed mantle cell lymphoma. Cancer. 113(3). 508–514. 170 indexed citations

17.

Jatoi, Aminah, Patrick A. Burch, David W. Hillman, et al.. (2007). A Tomato-Based, Lycopene-Containing Intervention for Androgen-Independent Prostate Cancer: Results of a Phase II Study from The North Central Cancer Treatment Group. Urology. 69(2). 289–294. 53 indexed citations

18.

Jatoi, Aminah, Philip J. Stella, Nathan R. Foster, et al.. (2006). Docetaxel and capecitabine in patients with metastatic adenocarcinoma of the stomach and gastroesophageal junction: a phase II study from the North Central Cancer Treatment Group. Annals of Oncology. 17(4). 652–656. 42 indexed citations

19.

Martin, Ronald F. & Patrick J. Flynn. (1997). THE ACUTE ABDOMEN IN THE CRITICALLY ILL PATIENT. Surgical Clinics of North America. 77(6). 1455–1464. 6 indexed citations

20.

Ascensão, João L., Patrick J. Flynn, Arne Slungaard, et al.. (1984). Quinidine-Induced Neutropenia: Report of a Case with Drug-Dependent Inhibition of Granulocyte Colony Generation. Acta Haematologica. 72(5). 349–354. 12 indexed citations

Rankless uses publication and citation data sourced from OpenAlex, an open and comprehensive bibliographic database. While OpenAlex provides broad and valuable coverage of the global research landscape, it—like all bibliographic datasets—has inherent limitations. These include incomplete records, variations in author disambiguation, differences in journal indexing, and delays in data updates. As a result, some metrics and network relationships displayed in Rankless may not fully capture the entirety of a scholar's output or impact.

Explore authors with similar magnitude of impact